ETNB - 89bio completes enrollment in phase 2 trial for NASH treatment
- 89bio ( NASDAQ: ETNB ) said it had completed enrollment of 219 patients in the Phase 2b trial of its drug, pegozafermin, to treat NASH.
- The company expects to report topline data from the trial, Enliven, in the first quarter of 2023.
- ENLIVEN is a placebo-controlled Phase 2b trial in biopsy-confirmed NASH patients with fibrosis stage 2 or 3.
- Patients will receive either one of two weekly doses (15mg or 30mg) or an every two-week dose (44mg) of pegozafermin in a liquid formulation or placebo for 24 weeks.
For further details see:
89bio completes enrollment in phase 2 trial for NASH treatment